Casebia is a novel joint venture focused on the development of breakthrough therapies using the promising CRISPR/Cas9 gene editing technology.
Cambridge, MA
Joined July 2016
- Tweets171
- Following377
- Followers725
- Likes174
This week our #MissionBay team had a great summer outing and #teambuilding event at @HandsonGourmet in #SanFrancisco. Everyone had a great time preparing and then enjoying their own meal with colleagues. We especially love the #CRISPR-themed @CasebiaTx aprons!
4
As part of our “Casebia Coast to Coast Backpack Drive” our Mission Bay and Cambridge teams had the opportunity to fill over 85 backpacks with school supplies to benefit local organizations and kids including @FSSBA @BFK2001 @CJPboston and @JewishBBBS.
7
We’re proud to share that @RobinWalker will be speaking on two panels at this week’s @ACI_Pharma's Women Leaders in Life Science Law & Compliance conference in Boston. She’ll share insights into her career and how she has become an impactful leader at Casebia.
Peter Nell, Ph.D., @CasebiaTx's SVP, Head of Corporate Strategy and Business Development, is featured in this excellent video from @Bayer's #CanWeLiveBetter campaign that hightlights advances in #hemophilia treatment bit.ly/2XMMtBS #geneediting #CRISPR #innovation
#Hemophilia treatment has improved significantly in the last 20 years with many patients now able to live full and healthy lives. But how close are we to a cure? bit.ly/2XMMtBS #CanWeLiveBetter
Casebia Therapeutics retweeted
Local biotechs UniQure, Casebia step up race for new hemophilia drugs bizjournals.com/boston/news/…
Senior Scientist Keith Abe from our #MissionBay office will be speaking next week at the @ACDbio Symposium in #SanFrancisco on the topic of ‘in vivo delivery of #Cas9 mRNA utilizing lipid nanoparticles in the mouse’ – learn more at: acdbio.com/acd-symposium-sou…
Next week on July 16th, our SVP and Head of Technical Operations Stephen Kennedy will be speaking on the topic of '#CMC challenges of combining complex #technologies' during the PharmaCentaur-organized industry meeting entitled ‘New Modalities: Breaking the Barriers’.
A successful @ISTH 2019 Congress including a presentation by @CasebiaTx Principal Scientist Alan Brooks on 'Therapeutic Levels of FVIII Generated by CRISPR/Cas9-mediated in vivo #GenomeEditing in #hemophiliaA Mice' & several productive meetings with our SVP Peter Nell. #ISTH2019
Breaking news: @CasebiaTx highlights novel #research in #geneediting therapeutics for #hemophiliaA; early-stage animal model #data presented during the @ISTH Congress demonstrates ability to edit hepatocytes & accurately tune production of FVIII #ISTH19 casebia.com/casebia-highligh…
Today, one of our beloved interns is headed off on her summer break and left some handmade gifts in the kitchen as a thank-you! It's the little things that make our Casebia community much more than just a workplace. Thank you, Amy, for the gift and we’ll see you in September!
Proud to have @CasebiaTx included in this video that highlights our work and other @LeapsByBayer joint ventures dedicated to discovering new treatments for genetic diseases nitter.gq/nowthisnews/status/113… #LeapsByBayer #DareToLeap #CanWeLiveBetter
This quoted post is unavailable.
Given the impact on the daily commutes for employees in our #Cambridge office, @CasebiaTx’s CEO recently joined with @kendallnow & other executives to urge state leaders to shift how we think about #transportation in #Massachusetts. Join the conversation: kendallsq.org/transportation…
#MotivationMonday: Moving blog from our collaborator @SeattleChildren’s Research Institute on a 7-year-old boy named Sonny battling a rare #autoimmune disorder called IPEX syndrome. Stories like Sonny's inspire us to advance new #geneediting therapeutics. pulse.seattlechildrens.org/s…
Our own Shyam Subramanian will speak at #NEXTGENCART on the topic of “Developing Manufacturing Platforms for Complex #GeneEdited #Tcell Therapies for #AutoimmuneDisease” based on our work with @SeattleChildren’s Research Institute via @AntibodyEng365 lifesciences.knect365.com/ca…
Tomorrow at 9am during the US East Coast Cell & Gene Therapy 2019 Strategy Meeting, our VP & Head of Ophthalmology Abraham Scaria will chair a roundtable discussion on the topic of 'mRNA-based gene transfer: Tool for gene and cell therapy'. Learn more at bit.ly/2WzG11k
We are excited to see our partner @CRISPRTX expanding their #geneediting #collaboration with @VertexPharma to treat genetic muscle diseases. There is a huge need. bit.ly/2Ip48px
We’re excited to expand our collaboration with @VertexPharma to develop best-in-class gene-edited therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1. Learn more here: bit.ly/2Ip48px $CRSP
2
From our headquarters in Cambridge to our research center in San Francisco, Casebia is proud to celebrate #PrideMonth with our employees, friends and families!
Today, we are excited to announce the appointment of our new SVP, Head of Technical Operations, Stephen Kennedy. See the full release: casebia.com/casebia-announce…
